The technical table on gender dysphoria is born at the Ministry of Health
It will have a pool of 29 experts. The Minister of Health, Orazio Schillaci, and the head of the Family Department, Eugenia Roccella, signed the decree.
ROME – An in-depth technical table on the treatment of gender dysphoria has been established at the Cabinet Office of the Ministry of Health. The decree was signed by the Minister of Health, Orazio Schillaci, and the head of the Family Department, Eugenia Roccella. The table is made up of < strong>a pool of 29 experts, including officials from the two ministries and members of various scientific societies (Siedp, Sigo, Siams , Sinpia, Sitcc, Sips, Sigo, Spi, Sip , Sigis and Sie).
The table was necessary, we read in the decree, considering the “non-homogeneity with which the professionals operate in the national territory” and, consequently, the need to “have guidelines that support them in the complex path”, which goes from diagnosis to possible therapies for dysphoric patients, because they are young with dysphoria gender, together with their families, can access the “best possible support from the National Health Service”.
The objective, therefore, is also to start a “reconnaissance of the methods of treatment of this condition in the territory national, including any related legal aspects, and the scientific evidence that has emerged in the international literature in the sector”.
Just today, meanwhile, there was a new question to the Ministry of Health by the leader of Forza Italia in the Senate,< strong> Maurizio Gasparri, to delve deeper into the issue relating to the gender dysphoria center of the ‘Careggi’ in Florence: “It seems that Careggi is not taking due account of all the indications of the ministry – Gasparri says – and that the administration of triptorelin is also continuing for new patients with gender dysphoria without adequate psychotherapeutic protection”.
Meanwhile yesterday, the president of the Italian Medicines Agency (Aifa), Robert Giovanni Nisticò, at a hearing in the Social Affairs Commission of the Chamber > had made it known that “in light of the scientific data which to date remain inconclusive on the benefit-risk relationship for adolescents with gender dysphoria disorder, the Aifa remains vigilant and sensitive to the evolution of the context international scientific andwill initiate a discussion and re-evaluation on the inclusion of triptorelin in the list of medicines established pursuant to law 648 of 1996“.